Superoxide Dismutase-3 Downregulates Laminin α5 Expression in Tumor Endothelial Cells via the Inhibition of Nuclear Factor Kappa B Signaling

Lorena Carmona-Rodríguez 1,†, Diego Martínez-Rey 1,‡, Paula Martín-González 1, Mónica Franch 2, Lydia Sorokin 3, Emilia Mira 1,§,¶ and Santos Mañes 1,*,†

1 Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB/CSIC), 28049 Madrid, Spain; lcarmona@cnb.csic.es (L.C.-R.); diego.martinez.rey@hotmail.com (D.M.-R.); pm681@cam.ac.uk (P.M.-G.)
2 Bioinformatics Unit, Centro Nacional de Biotecnología (CNB/CSIC), 28049 Madrid, Spain; monica.franch@perkinelmer.com
3 Institute of Physiological Chemistry and Pathobiochemistry and Cells in Motion Interfaculty Centre, University of Münster, 48049 Münster, Germany; sorokin@uni-muenster.de
* Correspondence: emira@cnb.csic.es (E.M.); smanes@cnb.csic.es (S.M.); Tel.: +34-91-585-4840 (S.M.)
† These authors contributed equally to this work.
‡ These authors contributed equally to this work.
§ These authors contributed equally to this work.
¶ These authors contributed equally to this work.

Simple Summary: Tumor-infiltrating lymphocytes determine cancer prognosis and the response to immunotherapy. The balance of laminin-α4/laminin-α5 isoforms in the endothelial basement membrane plays an instructive function in regulating the diapedesis of immune cells under inflammatory conditions. Previous studies showed that the extracellular superoxide dismutase (SOD3) induces laminin-α4, which is associated with improved disease-free survival of colorectal cancer patients. The aim of our study was to determine whether SOD3 also affects the expression of laminin-α5 in the tumor vasculature. The results showed that SOD3 differentially regulates laminin-α4 and laminin-α5 in the tumor endothelium. SOD3 promoted notable transcriptomic changes in tumor-stimulated endothelial cells, including the inhibition of the nuclear factor kappa B (NF-κB) pathway, an inducer of laminin α5 transcription. Therefore, high SOD3 levels in the tumor vasculature shifted the laminin α4/α5 balance towards the laminin-α4high/laminin-α5low phenotype, which is permissive for T cell diapedesis into tumors and explains the improved cancer immune surveillance associated to high SOD3 levels.

Abstract: The balance between laminin isoforms containing the α5 or the α4 chain in the endothelial basement membrane determines the site of leukocyte diapedesis under inflammatory conditions. Extracellular superoxide dismutase (SOD3) induces laminin α4 expression in tumor blood vessels, which is associated with enhanced intratumor T cell infiltration in primary human cancers. We show now that SOD3 overexpression in neoplastic and endothelial cells (ECs) reduces laminin α5 in tumor blood vessels. SOD3 represses the laminin α5 gene (LAMA5), but LAMA5 expression is not changed in SOD1-overexpressing cells. Transcriptomic analyses revealed SOD3 overexpression to change the transcription of 1682 genes in ECs, with the canonical and non-canonical NF-κB pathways as the major SOD3 targets. Indeed, SOD3 reduced the transcription of well-known NF-κB target genes as well as NF-κB-driven promoter activity in ECs stimulated with tumor necrosis factor (TNF)-α, an NF-κB signaling inducer. SOD3 inhibited the phosphorylation and degradation of IκBα (nuclear factor of the kappa light polypeptide gene enhancer in B-cells inhibitor alpha), an NF-κB inhibitor. Finally, TNF-α was found to be a transcriptional activator of LAMA5 but not of LAMA4; LAMA5 induction was prevented by SOD3. In conclusion, SOD3 is a major regulator of laminin balance in the basement membrane of tumor ECs, with potential implications for immune cell infiltration into tumors.
1. Introduction

Solid tumors are usually irrigated by an immature and dysfunctional vascular network. The hierarchical branching organization and the features associated with arterioles, capillaries and venules are not seen in a tumor’s vasculature. Rather, the vessels are tortuous and dilated with a chaotic blood flow (sometimes even stationary), resulting in the deficient transport of nutrients and oxygen, the latter leading to hypoxia. However, tumor cells not only adapt and survive under these stressful conditions, but also use this abnormal vascular network to create a shield that protects them from the immune system and therapeutic agents. The conversion of this immature endothelium into a more “normal” vascular network is, therefore, a promising therapeutic strategy for enhancing drug delivery and boosting immunotherapy [1–5].

Major drivers of the abnormal nature of tumor vasculature include inflammation, the composition of the extracellular matrix (ECM), and the accumulation of pro-angiogenic factors such as vascular-endothelial growth factor (VEGF)-A, in the tumor microenvironment (TME) [6]. VEGF-A not only triggers the proliferation, migration and sprouting of endothelial cells (ECs), but also greatly increases tumor vessel permeability by weakening vascular endothelial (VE)-cadherin-mediated EC junctions and interfering with pericyte-EC interactions [7,8]. Many of these proangiogenic factors are induced by inflammatory mediators, such as tumor necrosis factor (TNF)-α, acting on tumor and stromal cells via the nuclear factor kappa B (NF-κB) pathway [9]. NF-κB is a transcription factor assembled through the homo- or heterodimerization of five available subunits via the Rel-homology domain (a domain also involved in DNA binding) [10]. When processed proteolytically, the Rel family members p100 and p105 give rise to the p52 and p50 isoforms, respectively; these do not contain transactivation domains and need to interact with other family members, such as RelA (p65), RelB or c-Rel, to function as transcription factors [11,12]. p52/p50 dimers operate as transcriptional repressors [13].

The activity and nuclear translocation of RelA, RelB and c-Rel is regulated by inhibitors of the κB (IκB)-α and -β family proteins, which bind heterodimers in the cytoplasm. Most of the NF-κB-activating signals converge at the level of the IκB kinases (IKKα and IKKβ), which upon activation phosphorylate IκB inhibitors, priming them for ubiquitylation and proteasomal degradation [14]. This releases the NF-κB dimers, allowing them to enter the nucleus. It is noteworthy that all NF-κB signaling molecules are present in ECs, and their sustained activation in cancer and other pathologies leads to vascular disorganization and a reduction in the barrier function of the EC [11,15–17].

A central, but commonly overlooked, structural and functional element of blood vessels is the endothelial basement membrane (BM), a self-assembled layer of highly specialized glycoproteins, produced by ECs and pericytes, that underlies the former and encases the latter [18]. Endothelial BMs are not only structural scaffolds, but also contribute to the mechanical properties of blood vessels and transmit signals to endothelial and perivascular cells that may regulate blood flow and nutrient and oxygen supply [19]. Tumor vessels and endothelial sprouts also have a BM, but these membranes show abnormalities reminiscent of degenerated or regenerating vessels, including the loss of association with ECs, a varying thickness, and multiple layers [20]. A full understanding of the characteristics and molecular composition of the endothelial BM in tumor blood vessels is yet to be gained [21].

BM assembly is dependent on the initial self-assembly of laminins [22], a family of heterotrimeric ECM proteins. Sixteen laminin isoforms exist, the product of different combinations of five α, four β and three γ chains [23]. The biological role of the laminins is largely defined by their α-chain interaction with integrin and non-integrin receptors [24,25].

Keywords: basement membrane; laminin; immunotherapy; oxidative stress; diapedesis; endothelium; inflammation
Laminin α4 and α5 chains combine with laminin β1 and γ1 chains to form laminins 411 and 511, respectively, found in endothelial and smooth muscle BMs [18].

Previous studies have shown a patchy distribution of laminin α4 and α5 along the ‘vascular tree’ with little or no laminin α5 at postcapillary venules where leukocyte extravasation preferentially occurs [26–30]. Curiously, leukocyte adhesion to laminin α5-containing laminins is stronger than to laminin α4-containing isoforms, but their migration across laminin α4-positive BMs is faster [30]. The laminin α5/laminin α4 balance in the endothelial BM is, therefore, important in inflammation and potentially also in immune surveillance, as suggested by work in models of neuroinflammation, allograft rejection, and cancer [30–32]. In cancer, a recent study has shown a relationship between vascular normalization and changes in the expression of laminin α4-containing isoforms in the BM of tumor blood vessels, driven by high levels of the superoxide dismutase-3 (SOD3) in the TME [33]. Importantly, these SOD3-induced changes were also associated with the increased infiltration of cytotoxic CD8+ T cells and prolonged disease-free survival in patients with colorectal cancer.

SOD3 is an antioxidant metalloenzyme that localizes predominantly to the extracellular space where it associates with the ECM [34]. In fibroblasts and ECs, SOD3 can also be found in the nucleus and cytoplasm [35]. It is expressed in most tissues under physiological conditions, and accounts for up to 70% of extracellular SOD activity in the walls of healthy vessels. However, oncogenesis commonly represses SOD3 in many mouse and human tumors, and may contribute to the growth and progression of malignancies (reviewed in [36]). Analyzing how SOD3 re-expression affects the interaction of stromal and cancer cells in the TME is, therefore, of great interest.

SOD3 protects tissues from oxidative damage and prevents the generation of peroxynitrite from nitric oxide (NO) by catalyzing the dismutation of the superoxide anion. SOD3 activity thus preserves NO levels to act as an intra- and intercellular messenger in the endothelium. Indeed, the normalizing effects of SOD3 on the tumor vasculature are dependent on the NO-mediated stabilization of hypoxia-inducible factor (HIF)-2α, a transcription factor that upregulates VE-cadherin and reduces vascular leakage [37]. SOD3 also enhances the entry of T cells into tumors and improves immunotherapy through a mechanism that involves the induction of laminin α4 in a HIF-2α- and WNT-dependent manner [32]. Whether SOD3 also affects the expression of laminin α5 in tumor blood vessels is unknown. The present work shows that SOD3 triggers the transcription of the gene encoding laminin α4 (LAMA4) but represses that of the gene coding for laminin α5 (LAMA5) in ECs in vitro and in vivo, thus changing the laminin α4/laminin α5 ratio in tumor blood vessels. SOD3 repression of LAMA5 is dependent on the inhibition of the NF-κB pathway, here identified as a regulator of LAMA5 transcription in ECs under inflammatory conditions. The present work also identifies a complex transcriptional program under the control of SOD3 in ECs, responsible for the normalization of the tumor vasculature.

2. Materials and Methods
2.1. Cell Lines, Transfection and Stimulation

The mouse microvascular 1G11-mock and 1G11-SOD3, and the EG7-mock and EG7-SOD3 mouse thymoma cell lines have been described elsewhere [32,37]. Human dermal microvascular endothelial cells (HDMEC; Cascade Biologics, Portland, OR, USA) were cultured and transduced with recombinant adenoviruses encoding for human SOD3 or β-galactosidase (mock) as described [37]. N202.1A murine mammary cancer cells were provided by Dr. V. Bronte (Verona University, Verona, Italy) and cultured as previously described [38]. 1G11-SOD1 cells were generated by retroviral transduction with pRV-SOD1-IRES-GFP, cloned from pF151 pcDNA3.1(+)/SOD1WT (a gift from Dr. E. Fisher; Addgene plasmid #26397) [39] (Addgene; Watertown, MA, USA). Transduced cells were selected by cell sorting via GFP fluorescent emission using an MoFlo XDP device (Beckman Coulter; Brea, CA, USA).
HA-tagged SOD3 (pCMVSPORT6-HASOD3) was generated by inserting the HA tag sequence between the signal peptide and the mature SOD3 sequence in pCMVSPORT6-SOD3 (Open Biosystems; Huntsville, AL, USA). HEK-293T cells (ATCC; Manassas, VA, USA) were transfected with pCMVSPORT6-HASOD3 or pCMVSPORT6-SOD3 using Lipofectamine 2000 (Invitrogen; Waltham, MA, USA); 24 h post-transfection, the cells were cultured in basal medium (DMEM plus 0.1% BSA) for three days and cell-free conditioned medium collected and stored at −80 °C. Endothelial origin of 1G11 cells was verified regularly by VE-cadherin staining. Cell-free conditioned medium from N202.1A cells was obtained after cell culture in basal medium for five days. All cell lines were periodically tested for mycoplasmas.

For NF-κB activation, 1G11-mock or 1G11-SOD3 cells were starved for 1 h before stimulation with 1–10 ng/mL recombinant TNF-α (Peprotech; Cranbury, NJ, USA). In some experiments, cells were pretreated with BAY 11-7082 (1–2 µm, 1–2 h, 37 °C) (Selleckchem; Houston, TX, USA), followed by recovery in basal medium (6 h) before TNF-α stimulation.

2.2. Tumor Samples

C57BL/6J mice were supplied by The Jackson Laboratory (Bar Harbor, ME, USA) and SOD3EC-Tg mice generated as previously described [32]. For tumor generation, 2–5 month-old female mice were used. EG7-mock or EG7-SOD3 cells (5 × 10⁶/100 µL) were implanted subcutaneously into the indicated mouse strains (n = 7–9 mice/group) and tumors excised after 21 days. All mouse experiments were approved by the Comunidad de Madrid (PROEX 399/15) and the CNB Ethics Committees in strict accordance with the Spanish and European Union laws and regulations concerning the care and use of laboratory animals.

2.3. RT-qPCR

Total RNA was extracted from mouse tumors and cell lines using TRI-Reagent (Sigma Aldrich; Burlington, MA, USA). cDNA strands were synthesized from 0.5–2 µg total RNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems; Waltham, MA, USA), employing random primers. mRNA levels were quantified by qPCR in a Quant-Studio 5 Real-Time PCR System (Thermo Fisher; Waltham, MA, USA) using the SYBR EvaGreen-based reaction mix (Cmb-Bioline; Madrid, Spain) and specific primers (Table S1), employing β-actin for normalization. Relative quantities (Rq) (i.e., relative to the sample with the lowest expression or the control sample) were calculated using the 2−ΔΔCt method.

2.4. Microarray Analysis

1G11-mock and 1G11-SOD3 cells were incubated with N202.1A-conditioned medium for 6 h and total RNA isolated with TRI-Reagent. This was then further cleaned using the RNeasy Kit (Qiagen; Hilden, Germany). RNA quality was confirmed by electropherogram, employing an Agilent Technologies 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA, USA). The preparation of probes and hybridization were performed as described in the One-Color Microarray-Based Gene Expression Analysis Manual Ver. 6.5 (Agilent Technologies). RNA quality check, amplification, labeling, hybridization with Array SurePrint Mouse G3 8 × 60 (Agilent Technologies, G4852A) and initial data extraction were performed at the Genomic Service Facility at the Centro Nacional de Biotecnología (CNB-CSIC). Images were captured with an Agilent Microarray Scanner and spots were quantified using Feature Extraction Software (Agilent Technologies). Correction for the local background was performed using the normexp method with an offset of 50. Background corrected intensities were Log2-transformed and normalized by adjusting their quantiles [40]. Changes in expression over replicates was estimated using an empirical Bayes moderated t statistic (LIMMA) [41]. To control the FDR, probability values were corrected using the Benjamini–Hochberg method [42]. The FIESTA viewer (http://bioinfogp.cnb.csic.es/tools/FIESTA, accessed on 25 February 2022), developed by J.C. Oliveros (CNB Bioinformatics Core Facility),
was used to visualize the results. Principal components analysis (PCA) was performed to demonstrate similarity between expression profiles using ClustVis software [43]. A volcano plot was prepared using Prism 7.0 software (GraphPad; San Diego, CA, USA), with differentially expressed genes displayed in red (Fc > 2 or < −2, and FDR LIMMA < 0.05). All data files and normalized values were deposited in the NCBI Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo, accessed on 25 February 2022).

2.5. IPA and GSEA Analyses

The list of differentially expressed genes was subjected to functional analysis using Ingenuity Pathway Analysis (IPA) software v.6875226 (Ingenuity® Systems; Redwood City, CA, USA; www.ingenuity.com, accessed on 25 February 2022). Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathway Knowledge Base (IPKB). The core analysis was run using the default IPA settings: (i) the data source included all species, tissues and cell lines; (ii) interactions were queried for all genes stored within the IPKB; and (iii) no fold-change cut-off was specified. The significance of the canonical pathways was calculated according to the IPA user’s manual: (1) the ratio of the number of genes from the dataset that map to the pathway over the total number of genes that make up the pathway was determined; and (2) Fisher’s exact test was used to calculate a p value determining the probability that the association between the genes in the dataset and the canonical pathway was explained by chance alone. A pathway was considered significant when p < 0.05.

For Gene Set Enrichment Analysis (GSEA) [44], Log2 ratios and the weight punctuation system were used as classification metrics. The gene sets for the canonical and non-canonical NF-κB pathways were obtained from the Molecular Signatures Database v. 6.0 (http://software.broadinstitute.org/gsea/msigdb/index.jsp, accessed on 25 February 2022), and the analysis performed with those genes differentially expressed (as determined in microarray analyses) and showing an FDR of <0.25. GSEA was undertaken using the default parameters, that is, collapsing each probe set into a single vector, and using a permutation number of 1000 and the permutation type “gene-sets”.

2.6. Immunofluorescence Staining

Mock-, SOD3- or SOD1-transfected 1G11 cells were seeded on 1% gelatin-coated Nunc Lab-Tek chamber slides (Nunc; Rochester, NY, USA), fixed with methanol (10 min, −20 °C), and stained with rabbit anti-laminin α5 (antibody 504, described in [45]; or PAC078Mu01 antibody, Cloud Clone; Houston, TX, USA) or goat anti-laminin α4 (N20, sc-16589) (Santa Cruz Biotechnology; Dallas, TX, USA), followed by Alexa488- or Alexa594-labeled secondary antibodies (Thermo Fisher). The staining of 1G11 cells with anti-hemagglutinin (HA) tag antibody (clone 16B12) (Covance; Burlington, NC, USA) and p65 (RelA, clone L8F6) (Cell Signaling; Danvers, MA, USA) was performed after fixation with 4% paraformaldehyde (15 min, 20 °C) and permeabilization with 0.3% Triton X-100 (5 min, 20 °C). Tumor sections (10 µm) from snap-frozen (in OCT medium) (Sakura; Torrance, CA, USA), rabbit anti- laminin α5 (antibody 504) or goat anti-laminin α4 (N20, sc-16589; Santa Cruz Biotechnology), followed by appropriate fluorescently labeled secondary antibodies. In all cases, samples were mounted in 4,6-diamidino-2-phenylindole (DAPI)-containing Fluoromount-G (SouthernBiotech; Birmingham, AL, USA). Images were analyzed using a Leica DM RB (Wetzlar, Germany) equipped with an Olympus DP70 camera (Tokyo, Japan) at 200× or 400× total magnification (20× or 40× objective), or an Olympus Fluoview 1000 confocal microscope with a 60× 1.4 oil plan-Apo objective.

For quantification of laminin α5 and laminin α4 staining intensities in tumor sections, images were transformed to 8-bit versions with ImageJ software and, after threshold adjustment, the Image calculator tool was used to select coincident CD31- and laminin α5/α4-stained regions. The laminin/CD31 ratio was then calculated. For laminin α5 and
laminin α4 quantification in cultured ECs, mean fluorescence intensity was quantified using the ImageJ tool. An in-house open-source MATLAB-based computational platform was developed and used for automatic quantification of p65 nuclear staining. Nuclei were segmented using DAPI images and this segmentation used with the Alexa546 channel to measure the p65-stained pixels within the nuclear area; the ratio of nuclear staining to total nuclear area was then calculated.

2.7. Immunoblot and Chase Experiments

1G11 transfectants and human HEK-293T (used as a human SOD1 positive control) cells were lysed with RIPA buffer, and the products resolved by SDS-PAGE and transferred to membranes for immunoblot analysis with anti-SOD1 (NBP2-24915) (NOVUS Biologicals; Centennial, CO, USA), anti-p65 (L8F6) (Cell Signaling; Danvers, MA, USA), anti-β-actin (AC-15) (Sigma Aldrich; Burlington, MA, USA) or anti-tubulin (DM 1A) (Sigma Aldrich; Burlington, MA, USA) antibodies. SOD3 or HA-SOD3 was analyzed in conditioned medium using anti-SOD3 (M-106, sc-67089) (Santa Cruz Biotechnology) or anti-HA (clone 16B12) (Covance; Burlington, NC, USA) antibodies, respectively; loading control was by Ponceau staining. For laminin α4 and laminin α5 detection, RIPA cell extracts from 1G11-mock and 1G11-SOD3 cells were resolved in 4%–12% NuPAGE gels in MOPS SDS running buffer (ThermoFisher; Waltham, MA, USA), transferred to membranes using 48 mM Tris-HCl pH 8.3, 390 mM glycine, 0.1% SDS, 20% methanol, and immunoblotted sequentially with anti-laminin α5 (antibody 504), anti-laminin α4 (antibody 377b), anti-SOD3 and anti-β-tubulin (clone DM1A; Sigma Aldrich; Burlington, MA, USA) antibodies.

For chase experiments, 1G11-mock and 1G11-SOD3 cells grown in basal medium were pretreated (1 h, 37 °C) with 100 µg/mL cycloheximide (CHX; Sigma Aldrich; Burlington, MA, USA), followed by TNF-α (1 ng/mL) stimulation still in the presence of CHX. After cell lysis and transfer, membranes were blotted with anti-IκBα (44D4) (Cell Signaling; Danvers, MA, USA) and anti-tubulin antibodies. The IκBα/tubulin ratio was calculated from densitometry using ImageJ software. Phospho-IκBα kinetics were analyzed in 1G11-mock or 1G11-SOD3 cells grown in basal medium after treatment with the proteasome inhibitor MG132 (10 µM) (Selleckchem; Houston, TX, USA). Cell lysates were immunoblotted with anti-phospho(Ser32/36)-IκBα (5A5) (Cell Signaling; Danvers, MA, USA) and anti-tubulin antibodies, and the ratio calculated as above.

2.8. SOD Activity Assays

Exponentially growing 1G11-mock and 1G11-SOD1 cells were incubated (16 h) with N202.1A cell-conditioned medium in the presence or absence of the SOD mimetic Mn(III) tetrakis(4-benzoic acid)porphyrin (MnTBAP; 100 µm) (Calbiochem; San Diego, CA, USA). Cells were then stained with the cell-permeating superoxide probe dihydroethidium (DHE; 2 µm, 30 min, 37 °C) (Invitrogen; Waltham, MA, USA), which becomes red after oxidation. Cell extracts from 1G11-mock and SOD1 cells and conditioned medium from HEK-293T cultures enriched in untagged or HA-tagged SOD3 were assayed for SOD activity using the OxiSelect Superoxide Dismutase Activity Assay Kit (Cell Biolabs; San Diego, CA, USA) according to the manufacturer’s indications.

2.9. NF-κB Promoter Assay

1G11-mock and 1G11-SOD3 cells were co-transfected with p(NF-κB)3x-LUC (kindly provided by Dr. M. Ricote [CNIC]) and pRL-SV40-LUC plasmids (ratio 4:1). After 48 h, cells were stimulated with N202.1A-conditioned medium, and firefly and Renilla luciferase activities measured using the Dual Luciferase Reporter Assay System (Promega; Madison, WI, USA).

2.10. ELISA and Flow Cytometry

CCL2 was measured in cell-free supernatants collected from 1G11-mock and 1G11-SOD3 cultures (48 h) by ELISA using the mouse MCP-1 ELISA MAX Standard Set
(Biolegend; San Diego, CA, USA). For VCAM-1 analysis, 1G11-mock and 1G11-SOD3 cells were stained with anti-CD106-biotin antibody (clone 429) (Biolegend) followed by streptavidin-phycoerythrin, and analyzed by FACS using a FC-500 Cytomics device (Becton Dickinson; Franklin Lakes, NJ, USA).

2.11. Bioinformatic Analyses

The association between LAMA5 levels and CD8+ T cell infiltration was analyzed by TIMER algorithm (https://cistrome.shinyapps.io/timer/, accessed on 25 February 2022). Spearman’s correlation coefficients and p-values were provided by the program. The relationship between LAMA5 expression and tumor prognosis was analyzed using the Kaplan-Meier plotter database (http://kmplot.com/analysis/, accessed on 25 February 2022) [46].

2.12. Statistical Analyses

Data are shown as means ± SEM unless otherwise indicated. Individual values are also shown; the number of replicates is given in figure legends. For data with a Gaussian distribution and homogeneity of variance, differences were examined using the two-tailed Student’s t-test for comparison of two independent groups, and one- or two-way ANOVA with Dunnett’s or Bonferroni’s post-hoc correction for multiple comparisons. When these requirements were not fulfilled, data were analyzed using non-parametric tests (Mann-Whitney). Significance was set at p < 0.05. All calculations were performed using Prism 7.0 software.

3. Results

3.1. SOD3 Downregulates Laminin α5 Expression in the Tumor Vasculature

Previous studies in immunocompetent mice with EG-7 tumors (a thymoma) showed that the forced expression of SOD3 in neoplastic and endothelial cells correlated with enhanced perivascular levels of laminin α4-containing isoforms [32]. In addition, SOD3 overexpression in tumor and endothelial cells was associated with an improved response to the adoptive transfer of tumor-specific CD8+ T cells, suggesting that SOD3 provides a permissive signal for tumor infiltration by these cells [32]. Here, these tumor samples were analyzed by immunofluorescence to see whether SOD3 also affects laminin α5 expression in the tumor vasculature.

In tumors induced by control (EG7-mock) and SOD3-overexpressing (EG7-SOD3) cancer cells (Figure 1A), laminin α5 staining only appeared in close proximity to the endothelial cell marker CD31+ (Figure 1B), suggesting localization in the endothelial BM. Importantly, SOD3 overexpression in neoplastic cells was associated with less intense laminin α5 immunofluorescence staining (Figure 1B) and a significant reduction in the laminin α5-positive area (Figure 1C) compared to mock tumors. The importance of endothelial SOD3 expression on laminin α5 levels was determined using EG7-mock tumors implanted in a bi-transgenic mouse model generated by crossing the loxP-SOD3KI [37] and Tie2-Cre mouse lineages. This bi-transgenic mouse (SOD3 EC-Tg) expresses SOD3 specifically in the tumor endothelium [32]. The laminin α5 staining intensity and stained area were reduced in tumors from these mice compared to their non-transgenic (SOD3 f/f) counterparts (Figure 1D–F), suggesting that SOD3-induces laminin α5 downregulation.

To further investigate a potential differential regulation of LAMA4 and LAMA5 expression by SOD3, EG7 tumors implanted in SOD3 EC-Tg and SOD3 f/f mice were double stained with laminin α4 and laminin α5-specific antibodies. Whereas laminin α5 staining was intense in the tumors implanted in the SOD3 f/f mice, laminin α4 staining was markedly increased in the vessels of EG7 tumors grafted into the SOD3 EC-Tg mice (Figure 1G; low magnification images are provided in Figure S1). Determination of the laminin α4- and α5-stained areas in these tumors revealed a higher laminin α5/α4 ratio in the SOD3 f/f than in the SOD3 EC-Tg tumors (Figure 1H). Importantly, measurement of LAMA4 and LAMA5 mRNA levels revealed a reduced LAMA5/LAMA4 ratio in tumors engrafted in SOD3 EC-Tg
compared to those in SOD3<sup>f/f</sup> mice (Figure 1I), supporting the function of SOD3 in the balance of these laminin isoforms.

**Figure 1.** SOD3 downregulates laminin α5 and modifies the laminin α5/laminin α4 ratio in the tumor vasculature. (A) Diagram of tumor generation by subcutaneous (s.c.) injection of EG7-mock or EG7-SOD3 cells into C57BL6 mice (n = 7 mice/group). (B) Laminin α5 (green) and CD31 (red) staining from tumors as in A; nuclei were DAPI counterstained (blue). Representative images are shown. Scale bars 50 µm. (C) Stained laminin α5 and CD31 areas were quantified using Image J software with images as in B. The stained laminin α5 area is expressed as the percentage of that determined for CD31 (n = 9 fields/condition). * p < 0.05; two-tailed t-test. (D) Diagram of s.c. EG7 tumors in endothelial cell-specific SOD3 transgenic (SOD3<sup>EC-Tg</sup>) and control (SOD3<sup>Cre<sup>-</sup>/<sup>-</sup></sup>) mice (n = 9 mice/group). (E) Representative images of laminin α5 (green) and CD31 (red) staining of EG7 tumors in SOD3<sup>EC-Tg</sup> and SOD3<sup>f/f</sup> mice; nuclei were DAPI counterstained (blue). Scale bars 50 µm. (F) Quantification of stained laminin α5 area expressed as a percentage of the stained CD31 area using images as in E (n = 8–9 fields/condition). ** p < 0.01; two-tailed t-test. (G) Representative images of stained laminin α5 (green) and laminin α4 (red) EG7 tumors implanted in SOD3<sup>f/f</sup> and SOD3<sup>EC-Tg</sup> mice; nuclei were stained with DAPI (blue). Scale bars 25 µm. (H) Quantification of the laminin α5/laminin α4 ratio, determined as that between the stained area for each protein (n = 7–8 fields/condition). ** p < 0.01; Mann-Whitney test. (I) Ratio of the relative LAMA5 and LAMA4 mRNA levels isolated from EG7 tumors grafted into SOD3<sup>Cre<sup>-</sup></sup> and SOD3<sup>EC-Tg</sup> mice. Each dot represents the mean of a triplicate from an independent tumor sample. * p < 0.05; Mann-Whitney test. The tumor growth kinetics, survival data and SOD3 expression of the tumors here analyzed have been previously reported [32].
3.2. Extracellular SOD3 Represses LAMA5 Transcription in Endothelial Cells

The above results indicate that high SOD3 levels in the tumor milieu are associated with a reduction in laminin α5 in the endothelial BM. Intriguingly, this occurred when SOD3 was produced by tumor or endothelial cells. A mouse microvascular endothelial cell line, 1G11, modified to overexpress SOD3 [37] was used to clarify whether this laminin α5 downregulation is a direct consequence of SOD3 activity on the ECs. We found that LAMA5 mRNA (Figure 2A) and laminin α5 protein levels as detected by immunofluorescence (Figure 2B,C) and immunoblot (Figures 2D,E and S2) were significantly reduced in SOD3-overexpressing 1G11 cells. Notably, SOD3 overexpression increased laminin α4 protein levels (Figure 2D,E), as previously reported [32,33].

To rule out that the effect of SOD3 on LAMA5 transcription was the consequence of aberrant SOD3 localization due to overexpression, LAMA5 expression levels were analyzed in unmodified 1G11 cells incubated with extracellular SOD3. The source of this extracellular SOD3 was conditioned serum-free medium from human embryonic kidney (HEK)-293T cells transfected with murine SOD3 or hemagglutinin (HA)-tagged SOD3 (Figure 2F). Immunoblots showed the ectopic expression of both untagged and HA-tagged SOD3 in the conditioned medium (CM) (Figures 2G and S3); moreover, both forms were enzymatically active (Figure 2H). In agreement with previous reports [35], extracellularly added HA-SOD3 entered into the 1G11 cells and accumulated mainly in the cytosol, although some cells showed a little nuclear staining (Figure 2I). More importantly, the addition of extracellular SOD3 significantly reduced the levels of LAMA5 mRNA (Figure 2J) and the intensity of the laminin α5 staining (Figure 2K,L), but increased laminin α4 staining in these 1G11 cells (Figure S4), in agreement with previous reports [32]. These results indicate that extracellular SOD3 exerts a differential regulation of laminin α4 and laminin α5 in EC, which is not an artifact of overexpression.

3.3. LAMA5 Transcription Is Not Affected by SOD1

Experiments were next performed to determine whether other antioxidant enzymes mimic the effect of SOD3 on LAMA5 transcription. For this, 1G11 cells stably expressing the cytosolic SOD1 isoform were generated (1G11-SOD1 cells). These expressed high SOD1 mRNA and protein levels (Figures 3A,B and S5), and showed rescued superoxide levels compared to mock transfected cells, as determined by staining with the cell-permeating probe DHE after exposition with the conditioned medium from N202.1A breast cancer cells, used as a prototypic tumor cell line able to induce oxidative stress in the endothelium (Figure 3C). Moreover, SOD activity was greater in cell extracts from 1G11-SOD1 cells compared to control cells (Figure 3D).

Tests were then undertaken to determine whether SOD1 overexpression affects LAMA5 expression. No differences in LAMA5 mRNA and laminin α5 protein levels were found between the 1G11-mock and SOD1-overexpressing cells (Figure 3E–G). However, both the 1G11-SOD3 and 1G11-SOD1 cells showed greater LAMA4 mRNA transcription compared to their corresponding control cells (Figure 3H). Therefore, while SOD1 and SOD3 promote LAMA4 expression, only SOD3 suppresses LAMA5 expression.
Figure 2. SOD3 downregulates laminin α5 expression in endothelial cells. (A) LAMA5 mRNA levels in 1G11-mock and 1G11-SOD3 cells determined by RT-qPCR. Each dot represents the mean of a triplicate from an independent experiment. *p < 0.05; two-tailed t-test. (B) Laminin α5 (green; antibody 504) staining in 1G11-mock and 1G11-SOD3 cells; nuclei were DAPI counterstained (blue). Representative images are shown. Scale bars 50 µm. (C) Quantification of laminin α5 mean fluorescence intensity from images as in B (n = 5 fields/condition). *p < 0.05; two-tailed t-test. (D) Cell extracts from 1G11-mock and 1G11-SOD3 were resolved by 4–12% SDS-PAGE and sequentially immunoblotted with anti-laminin α5, anti-laminin α4, anti-SOD3 and anti-α tubulin, as loading control. (E) Densitometric quantification of laminin α5/tubulin and anti-laminin α4/tubulin ratio from immunoblots as in (D) (n = 3). *p < 0.05; two-tailed t-test. (F) Diagram of the HA-tagged SOD3 form cloned in the pCMVSPORT6 vector. SP, signal peptide; HA, influenza hemagglutinin. (G) Conditioned medium (CM) from cells transfected with the empty vector (control), SOD3 or HA-SOD3, resolved by SDS-PAGE. Transferred proteins were visualized with Ponceau red (upper panel) and then immunoblotted with anti-SOD3 (middle) and anti-HA antibodies (lower). Representative of three experiments. (H) SOD activity in SOD3 and HA-SOD3 CM. (I) 1G11 cells were incubated with control or HA-SOD3 CM and SOD3 visualized with an anti-HA antibody (green); nuclei were DAPI-counterstained (blue). Scale bars 25 µm. (J) Relative LAMA5 mRNA levels in 1G11 cells incubated with control or HA-SOD3 CM (n = 3). **p < 0.01; two-tailed t-test. (K) Laminin α5 staining (green; antibody 504) in 1G11 cells incubated with control or HA-SOD3 CM; nuclei were DAPI-counterstained (blue). Scale bars 50 µm. (L) Quantification of laminin α5 mean fluorescence intensity from (K) (n = 5 fields/condition). *p < 0.05; two-tailed t-test.
Figure 3. SOD1 does not affect laminin α5 expression in endothelial cells. (A) mRNA levels of human SOD1 in 1G11-mock and 1G11-SOD1 cells, as determined by RT-qPCR. Each dot represents the mean of a triplicate from an independent experiment *** p < 0.001; two-tailed t-test. (B) Human SOD1 protein levels in 1G11-mock and 1G11-SOD1 cells as determined by immunoblotting; HEK-293T cells were used as a human SOD1 reference. Immunoblots were rehybridized with an anti-β-actin antibody as a loading control. A representative experiment is shown. (C) 1G11-mock and 1G11-SOD1 cells were incubated (14 h) with the conditioned medium from N202.1A tumor cell line cultures (MCT) and then stained with DHE (red); nuclei were DAPI-counterstained (blue). Treatment with the SOD mimetic MnTBAP was used as control (right panels). Scale bars 25 µm. (D) SOD activity in 1G11-mock and 1G11-SOD1 cell extracts. (E) Relative LAMA5 mRNA levels in 1G11-mock and 1G11-SOD1 cells. Each dot represents the mean of a triplicate from an independent experiment (n = 5). p = 0.32, two-tailed t-test. (F) Representative images of laminin α5 (green; PAC078MV01) staining in 1G11-mock and 1G11-SOD1 cells; nuclei were DAPI counterstained (blue). Scale bars 50 µm. (G) Quantification of laminin α5 mean fluorescence intensity from the images as in (F) (n = 5 fields/condition). p = 0.58; two-tailed t-test. (H) Relative LAMA4 mRNA levels in 1G11-mock, 1G11-SOD3 and 1G11-SOD1 cells. Each dot represents the mean of a triplicate from an independent experiment (n = 6). ** p < 0.01, *** p < 0.001, two-tailed t-test.

3.4. SOD3 Modifies the Transcriptional Program of Endothelial Cells

To investigate the mechanism by which SOD3 might modulate LAMA5 transcription, the transcriptomic profiles of 1G11-mock and 1G11-SOD3 cells were analyzed. To resemble the situation of the tumor endothelium, both subsets of ECs were exposed to the conditioned medium of N202.1A tumor cell cultures prior to analysis. Principal component analysis (PCA) clearly distinguished the 1G11-mock and 1G11-SOD3 cell gene expression profiles (Figure 4A). A total of 1682 genes showed a difference in expression (fold change [Fc] of >2 or <−2, false discovery rate [FDR] < 0.05; 1132 genes upregulated, 550 downregulated) between the mock and SOD3-overexpressing 1G11 cells (Figure 4B). These differentially expressed genes coded for cytoplasmic (40.25%), nuclear (26.13%), plasma membrane (12.93%) and extracellular (7.77%) proteins. Other differentially expressed RNAs (12.93%) represented long, non-coding RNAs, pseudogenes or unknown sequences. An 18.9 Fc increase in SOD3 expression was recorded for the 1G11-SOD3 cells, which also showed the upregulation of genes involved in the negative regulation of apoptosis (IGF-I, TNFAIP8L1, ECSCR, FAIM2), G-protein signaling (GPS1, RGS10, RGS20, RAB3B), and metabolic and mitochondrial processes (AKR1B10, NDUFC2, SOD2, MPC2, GPH1, COX6C, TIMM8A1). In contrast, SOD3 repressed genes involved in inflammation and leukocyte trafficking, including several chemokines (CCL2, CCL7, CXCL17, CXCL10) and integrins and their reg-
ulators (CIB3, VCAM-1, ICAM-1). Significant SOD3-induced LAMA5 downregulation was also observed, whereas LAMA4 tended to be upregulated in 1G11-SOD3 cells (Figure 4C). WISP2, a positive regulator of LAMA4 [32], was also significantly upregulated (Fc + 12.36; FDR = 6.9 × 10^{-3}) in these cells.

**Figure 4.** SOD3 induces a specific transcriptional program in 1G11 endothelial cells. (A) PCA plot using the rLog-transformed values from the microarray analysis of 1G11-mock and 1G11-SOD3 cells. Each dot represents an independent experiment. (B) Volcano plot of differentially expressed genes in 1G11-mock and 1G11-SOD3 cells. Red dots indicate genes with an absolute fold change (Fc) > 2 and an FDR of <0.05. Some of the genes with the highest variation are indicated. (C) Average Fc of the laminin chains as detected by the microarray (n = 3). (D) Selection of Ingenuity Pathway Analysis (IPA) top canonical pathways regulated by SOD3, listed according to their p value (lowest p = 0.02). The color of the bars indicates pathway activation (orange) or inhibition (blue) based on a Z-score; gray indicates no activity pattern available. The black circles represent the ratio of the number of differentially expressed genes in each pathway over the total number of genes in that pathway. (E) Top 30 upstream regulators identified by IPA (lowest p-value = 1.7 × 10^{-14}). Colors indicate activation (orange) or inhibition (blue) based on a statistical Z-score. (F) Upstream regulator analysis of differentially expressed genes in 1G11-SOD3 cells related to the NF-κB network. Color code is indicated at the left. (G) GSEA of the canonical (top) and non-canonical (bottom) NF-κB target genes in 1G11-SOD3 and 1G11-mock cells. Enrichment plots (green); the ranked list metric for each gene as a function of the rank in the ordered dataset (bottom) is shown. The p values and FDRs are indicated.
The gene expression data were also subjected to Ingenuity Pathway Analysis (IPA). Many of the canonical pathways significantly regulated by SOD3 were related to inflammatory processes, oxidative stress and actin remodeling (Figure 4D). Among them, the Wnt/β-catenin pathway ($p = 0.02$, z-score: 0.53), previously implicated in LAMA4 induction in tumor endothelium [32], was activated. Four molecular networks with an IPA score of >30 (number of genes participating in a particular network) were also identified (Figure S6). The enrichment of downregulated genes involved in the “antimicrobial and inflammatory response” network is noteworthy, suggesting an anti-inflammatory activity for SOD3. In agreement with this idea, a large number of upstream transcriptional regulators related to the NF-κB pathway showed a z-score compatible with inhibition in the 1G11-SOD3 cells (Figure 4E). Indeed, NF-κB targeted the transcription of 38 differentially expressed genes (FDR < 0.05), most of them repressed in 1G11-SOD3 cells (Figure 4F). Gene set enrichment analyses (GSEA) confirmed the negative regulation of NF-κB target genes in both the canonical and non-canonical pathways in 1G11-SOD3 cells compared to mock cells (Figure 4G). Together, these data reveal the inhibition of the NF-κB pathway as a major function of SOD3 in 1G11 cells.

3.5. SOD3 Attenuates the NF-κB Pathway in Endothelial Cells

To confirm the role of SOD3 affects the activation of the canonical NF-κB pathway, 1G11-mock and 1G11-SOD3 cells were stimulated with TNF-α (a well-established activator of this pathway), and the nuclear translocation of the p65 (RelA) subunit was analyzed by immunofluorescence. Under basal conditions (unstimulated), nuclear p65 levels were higher in the mock than in the SOD3-expressing cells (Figure 5A). Nonetheless, differences became significant after TNF-α stimulation, which triggered massive p65 nuclear translocation in the mock cells, but only a modest translocation in the 1G11-SOD3 cells (Figure 5A,B). This reduction of p65 nuclear translocation in the 1G11-SOD3 cells correlated with the reduced transcription of NF-κB target genes, such as CCL2, CXCL10, EAS and VCAM-1 (Figure 5C). CCL2 and VCAM-1 protein levels were also reduced in 1G11-SOD3 compared to the mock cells (Figure S7A,B), in agreement with their transcriptional downregulation. Remarkably, ICAM-1 mRNA levels were comparable between mock- and SOD3-overexpressing cells, either in basal conditions or after TNF-α stimulation (Figure S7C).

To confirm a role for SOD3 in NF-κB-mediated transcription, 1G11-mock and 1G11-SOD3 cells expressing a NF-κB-luciferase reporter construct were stimulated with conditioned medium from the N202.1A tumor cell line. This increased NF-κB promoter activity in a time-dependent manner, but more strongly in the 1G11-mock than in the 1G11-SOD3 cells (Figure 5D).
Figure 5. SOD3 attenuates NF-κB transcriptional activity in endothelial cells. (A) Representative images of RelA (p65) staining (red) in unstimulated (0) and TNF-α-stimulated (20 min) 1G11-mock and 1G11-SOD3 cells; nuclei were DAPI-counterstained (blue). Scale bars 10 μm. (B) Percentage of the nuclear p65 stained area with reference to the total nuclear area as determined by DAPI staining (n = 4–6 fields/condition). *** p < 0.001, two-way ANOVA with Bonferroni post-hoc correction. (C) Relative CCL2, CXCL10, FAS and VCAM-1 mRNA levels in unstimulated and TNF-α-stimulated (1.5 h for CCL2 and CXCL10; 0.5 h for FAS and VCAM-1) 1G11-mock and 1G11-SOD3 cells (n = 3). Each dot represents the mean of a triplicate from an independent experiment. * p < 0.05, ** p < 0.01, *** p < 0.001, two-way ANOVA with Bonferroni post-hoc correction. (D) 1G11-mock and 1G11-SOD3 cells were transiently transfected with the NF-κB-luciferase firefly reporter and the promoter-less pRL-SV40-luciferase Renilla plasmids, and then stimulated with conditioned medium from N202.1A tumor cells. The relative NF-κB promoter activity was determined by the firefly/Renilla ratio (n = 6). * p < 0.05, two-tailed t-test.

3.6. SOD3 Inhibits the NF-κB Pathway by Stabilizing IκBα

The above results support the idea that SOD3 is a negative regulator of the transcriptional activity of NF-κB. It is noteworthy that 1G11-mock and 1G11-SOD3 cells showed similar p65 protein levels (Figure S8A,B), suggesting that SOD3 inhibits NF-κB transcription by post-translational mechanisms. The nuclear translocation of NF-κB is inhibited by IκB proteins, the degradation of which is regulated by phosphorylation [11]. To determine whether SOD3 affects IκBα degradation, 1G11-mock and 1G11-SOD3 cells were treated with cycloheximide (a protein synthesis inhibitor) and IκBα protein levels analyzed at different times after TNF-α stimulation (Figures 6A and S9). IκBα levels were significantly higher in the unstimulated 1G11-SOD3 than in the mock cells; however, TNF-α stimulation reversed these differences over time (Figure 6B). Indeed, the half-life of IκBα protein was comparable between 1G11-mock (17.83 ± 6.5 min) and 1G11-SOD3 (17.97 ± 6.02 min) cells after TNF-α stimulation, suggesting that SOD3 stabilizes IκBα but does not completely prevent its degradation after a strong stimulus. Although TNF-α stimulation increased IκBα mRNA levels, no differences were seen between the 1G11-mock and 1G11-SOD3 cells (Figure S8C), indicating that SOD3 regulates IκBα levels exclusively through post-translational mechanisms.
To gain further insight into how SOD3 stabilizes IkBα, IkBα ubiquitination was analyzed in unstimulated 1G11-mock and 1G11-SOD3 cells in the presence of MG132, a proteasome inhibitor. The time-dependent accumulation of phosphorylated and polyubiquitinated forms of IkBα was greater in the mock than in the SOD3-overexpressing cells (Figures 6C and S10). Densitometric analyses indicated a significant reduction in phosphorylated IkBα in the 1G11-mock compared to the SOD3 cells (Figure 6D). These results indicate that SOD3 overexpression inhibits NF-κB transcription by preventing IkBα phosphorylation, a key step in IkBα ubiquitination and degradation [10].

3.7. SOD3 Regulates LAMA5 Expression via the NF-κB Pathway

The NF-κB pathway has been reported to be a positive regulator of LAMA5 in colorectal cancer cells [47]. In the present work, NF-κB pathway activation was also seen to induce LAMA5 transcription in ECs in a time-dependent manner (Figure 7A). LAMA4 mRNA levels were, however, not affected by TNF-α stimulation, suggesting a specific effect of NF-κB on the LAMA5 promoter. The NF-κB-mediated regulation of LAMA5 was confirmed by the treatment of the 1G11-mock cells with BAY11-7082, which inhibits IkBα phosphorylation and hence NF-κB activation; this reduced LAMA5 expression and the intensity of laminin α5 staining (Figure 7B–D). Since SOD3 inhibits the NF-κB pathway, it was reasoned that SOD3-overexpressing cells should prevent LAMA5 induction after NF-κB stimulation. Indeed, TNF-α stimulation induced LAMA5 expression in 1G11-mock but not in 1G11-SOD3 cells (Figure 7E–G). These results suggest that high SOD3 levels reduce endothelial LAMA5 expression via the inhibition of the NF-κB pathway. It is remarkable that SOD3...
overexpression in human microvascular cells (HDMEC) downmodulated LAMA5 mRNA levels while increased those of LAMA4, and this was associated with a downregulation of NF-κB target genes, such as CCL2, CXCL10 and VCAM-1, compared to mock-transduced HDMEC cells (Figure S11). These results suggest that SOD3/NF-κB/LAMA5 pathway is also operative in human endothelial cells.

Figure 7. SOD3 restrains NF-κB-induced LAMA5 expression. (A) Time-course changes in the relative LAMA4 and LAMA5 mRNA levels in 1G11-mock and 1G11-SOD3 cells after TNF-α stimulation. Values were normalized against the unstimulated condition (time 0) (n = 3 independent experiments). ** p < 0.01, *** p < 0.001, two-way ANOVA with Bonferroni post-hoc correction. (B) Relative LAMA5 mRNA levels in vehicle- (DMSO) or BAY11-7082-treated 1G11 cells. ** p < 0.01, two-tailed t-test. (C,D) Representative images and quantification of laminin α5 staining in ECs. SOD3 also prevented the induction of LAMA5 expression by NF-κB, suggesting this pathway to be a major target for SOD3-induced LAMA5 repression. High levels of SOD3 in the milieu of EG7-SOD3 tumors grafted in syngeneic mice or EG7 tumors implanted in SOD3EC-Tg mice were also correlated with a reduction in laminin α5 staining.

4. Discussion

The balance of laminin α4/laminin α5 isoforms in the endothelial BM plays an instructive function in regulating the diapedesis of immune cells [23]. Understanding the molecular circuits that regulate the levels of these isoforms in the endothelial BM of tumor blood vessels might therefore be key in improving immune surveillance for cancer. The present work suggests that the antioxidant enzyme SOD3 is a negative regulator of laminin α5 expression in tumor ECs. SOD3 overexpression or incubation of an endothelial cell line with extracellularly added SOD3 was found to reduce LAMA5 mRNA and laminin α5 staining in ECs. SOD3 also prevented the induction of LAMA5 expression by NF-κB, suggesting this pathway to be a major target for SOD3-induced LAMA5 repression. High levels of SOD3 in the milieu of EG7-SOD3 tumors grafted in syngeneic mice or EG7 tumors implanted in SOD3EC-Tg mice were also correlated with a reduction in laminin α5 staining.
intensity in tumor blood vessels, supporting a role for SOD3/LAMA5 interactions in vivo. Importantly, SOD3 levels were also positively associated with high laminin α5 immuno-
taining in these tumors, which is likely to shift the laminin α4/α5 balance towards the
laminin α4high/laminin α5 low phenotype observed in postcapillaries at sites of leukocyte
extravasation [26,28,30]. Indeed, SOD3 has been linked with increased T cell infiltration and
immune surveillance in mouse and human tumors, an effect dependent on NO-induced
stabilization of HIF-2α in ECs [33]. A scenario is therefore proposed in which high levels of
SOD3 differentially regulates the transcription of LAMA4 and LAMA5 specifically in tumor
endothelium by acting on distinct transcriptional regulators: the stabilization of HIF-2α
for LAMA4 induction, and the inhibition of NF-κB for LAMA5 repression (see graphical
abstract).

A corollary to the model proposed above is that high levels of SOD3 might increase
the infiltration of anti-tumor effector T cells into the TME by reducing LAMA5 expression
in ECs; since high density of CD8+ T cells has been associated to better prognosis in some
types of cancer, LAMA5 levels might thus influence tumor prognosis. Supporting this
hypothesis, analysis of TCGA data with TIMER algorithm showed a negative correlation
between LAMA5 mRNA levels and the intratumor CD8+ T cell signature for some cancers
types, including stomach, lung and ovarian (Table S2). Notably, high LAMA5 expression in
tumors negatively impacted the survival of patients with gastric, lung and ovary tumors
(Figure S12). Although these data suggest an association between LAMA5, CD8+ T cell
density and tumor prognosis, they must be taken with caution since LAMA5 mRNA levels
recorded in these databases are derived from the whole tumor tissue, without distinction
between neoplastic and endothelial cells. Laminin-α5 can be a component of the basement
membrane of the tumor epithelium, regulating tumor cell proliferation and migration [48].
Therefore, laminin-α5 might have different activities in cancer prognosis depending of its
spatial compartmentalization.

In apparent contradiction, whereas SOD3 enhances tumor infiltration of effector T cells
in the TME by changing the laminin α4/α5 balance, also reduces the expression of endothe-
lial adhesion molecules required for leukocyte diapedesis. A possible explanation for this
conundrum is that, in contrast to previous studies [49], we found no changes in ICAM-1
transcription associated to SOD3 overexpression (Figure S7C). High ICAM-1 expression lev-
els on endothelial cells have been linked to T cell transcellular diapedesis [50,51], which is
also the preferred pathway for diapedesis of effector and effector memory CD8+ T cells [52].
Further research is needed to clarify the role of SOD3 on ICAM-1 transcription in the tumor
endothelium.

The present results are consistent with the concept that SOD3 inhibits inflammation by
targeting the NF-κB pathway [49,53–56], potentially by inhibiting IκB phosphorylation. IκB
proteins inhibit NF-κB translocation into the nucleus, an inhibitory mechanism overturned
by IκB phosphorylation (catalyzed by the IKK complex) [14]. In the present work, SOD3
overexpression did not change IκBα mRNA levels but reduced IκBα phosphorylation and
consequently its degradation, increasing IκBα levels and its inhibitory capacity. It should
be noted that major differences in IκBα levels were seen between the mock-transfected
and SOD3-overexpressing cells in the basal state, and that these differences disappeared
upon TNF-α stimulation. It may be that IκB does not totally prevent the constitutive
shuttling of NF-κB between the cytosol and nucleus, and that a low level of transcriptional
activity occurs in non-activated cells [57]. This basal NF-κB activity would depend on the
dissociation/re-association kinetics of the IκB/p65RelA interaction [58], which in turn is
determined by the concentration of the reactants. Immunoblot analyses showed SOD3 to
reduce IκBα phosphorylation and consequently increase the IκBα protein available under
basal conditions, changing the IκB/p65RelA ratio towards a more inhibitory state. After
strong stimulation, SOD3 attenuates but does not completely inhibit IκBα phosphorylation.
Therefore, SOD3 seems not to fully prevent the ubiquitination or proteosomal degradation
of IκB.
The precise mechanism by which SOD3 impairs IκBα phosphorylation deserves future exploration. A potential mediator might be NO; this is known to interfere with IκBα phosphorylation [59,60], and its levels are increased by the antioxidant activity of SOD3 [37]. However, an intriguing observation is that LAMA5 transcription is not affected by SOD1, another antioxidant enzyme that can increase NO levels in the cytoplasm [61]. Indeed, both SOD1 and SOD3 comparably induced LAMA4 transcription in 1G11 cells. This suggests that additional SOD3-specific mechanism(s) control the NF-κB pathway.

The relatively large number of genes showing changes in their expression due to SOD3 overexpression was unexpected. Some of these differentially regulated genes produce products involved in processes that are likely regulated by an antioxidant enzyme, such as NO signaling, the response to oxidative stress, or the activation of signaling pathways previously reported as influenced by SOD3, such HIF and WNT/β-catenin [32,37]. Some of the other processes identified, for example, the regulation of the sumoylation pathway, were unexpected and merit further study. It is also evident that many of the predicted regulators affected by SOD3 are controllers of inflammation; in addition to NF-κB, SOD3 might influence signaling pathways elicited by Toll-like receptors, type-II interferons and STAT transcription factors. It may be that SOD3 influences all these regulators by affecting a single master regulator of inflammation, such as NF-κB. Nonetheless, the observation that SOD3 can enter the nucleus of ECs opens up the possibility that it alters transcription in these cells by modifying epigenetic regulators through redox-induced or NO-mediated reactions [62–64].

5. Conclusions

In conclusion, this study shows that SOD3 represses the transcription of LAMA5 in tumor ECs. This activity is SOD3-specific and not shared by the antioxidant enzyme SOD1. SOD3-induced LAMA5 repression is associated to the inhibition of the NF-κB pathway, through a mechanism involving the prevention of IκBα phosphorylation and consequently its degradation. These results, plus those of earlier studies [32], highlight the potential of SOD3 to be a major player in the regulation of laminin α4 and laminin α5 in the endothelial BM of tumor vasculature, shifting the laminin α4/α5 balance towards a phenotype observed in postcapillaries at sites of leukocyte extravasation. SOD3 may thus increase the infiltration of anti-tumor effector cells into the TME, explaining the better prognosis associated with high SOD3 levels in some types of cancer.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14051226/s1, Figure S1: Differential regulation of laminin α5 and laminin α4 by SOD3 in tumors; Figure S2: Original immunoblots for Figure 2D; Figure S3: Original immunoblots for Figure 2G; Figure S4: Extracellular SOD3 upregulates laminin α4; Figure S5: Original immunoblots for Figure 3B; Figure S6: Molecular networks with an IPA score of >30; Figure S7: Effect of SOD3 overexpression in CCL2, VCAM-1 and ICAM-1 levels; Figure S8: p65 protein levels and relative IκB-α mRNA expression in 1G11-mock and 1G11-SOD3 cells; Figure S9: Original immunoblots for Figure 6A; Figure S10: Original immunoblots for cropped images in Figure 6C; Figure S11: Relative expression of laminins and NF-κB target genes in SOD3-overexpressing human endothelial cells; Figure S12: Association of laminin α5 levels with the prognosis of different cancers; Table S1: Primers used for RT-qPCR; Table S2. Correlation between LAMA5 and CD8 T cell infiltration in human cancers.

Author Contributions: Conceptualization, E.M. and S.M.; investigation, E.M., L.C.-R., D.M.-R.; GSEA, M.F.; software, P.M.-G.; validation, E.M., D.M.-R. and S.M.; resources and contribution of ideas, L.S.; writing—original draft preparation, S.M.; writing—review and editing, E.M., L.S., L.C.-R.; funding acquisition, S.M. All authors have read and agreed to the published version of the manuscript.
**Funding:** This research was funded by the Spanish Ministry of Economy and Competitiveness (SAF2017-83732-R), the Spanish Ministry of Science and Innovation (PID2020-116303RB-I00/MCIN/ AEI/10.13039/50110011033), the Comunidad de Madrid (B2017/BMD-3733; IMMUNOTHERCAN-CM), and the Asociación Española Contra el Cáncer (AECC; PRYGN211240MANE). D.M.-R. was supported by a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities and the EU European Social Fund (PRE2018-084023).

**Institutional Review Board Statement:** The animal study protocol was approved by the Comunidad de Madrid (PROEX 399/15) and the Centro Nacional de Biotecnología Ethics Committees in strict accordance with the Spanish and European Union laws and regulations concerning the care and use of laboratory animals.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data files and normalized values from transcriptomic analyses were deposited in the NCBI Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo, last accessed on 25 February 2022), and are accessible through the GEO Series accession number GSE189247. Other datasets from this study are available upon reasonable request to the corresponding authors.

**Acknowledgments:** The authors thank R.M. Peregil for technical assistance, M.C. Moreno and M.A. Sánchez for flow cytometry services (CNB-CSIC), J.C. Oliveros for transcriptomic analyses (CNB Bioinfo Facility), the Histology Facility of the CNB-CSIC for histological preparations, and V. Bronte, M. Ricote, and M. Torres for sharing reagents.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Song, Y.; Fu, Y.; Xie, Q.; Zhu, B.; Wang, J.; Zhang, B. Anti-angiogenic Agents in Combination with Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. *Front. Immunol.* 2020, 11, 1956. [CrossRef] [PubMed]
2. Ganss, R. Tumour vessel remodelling: New opportunities in cancer treatment. *Vasc. Biol.* 2020, 2, R35–R43. [CrossRef] [PubMed]
3. Quintela-Fandino, M.; Holgado, E.; Manso, L.; Morales, S.; Bermejo, B.; Colomer, R.; Apala, J.V.; Blanco, R.; Muñoz, M.; Caleiras, E.; et al. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: A pilot clinical trial. *Breast Cancer Res.* 2020, 22, 124. [CrossRef]
4. Yang, T.; Xiao, H.; Liu, X.; Wang, Z.; Zhang, Q.; Wei, N.; Guo, X. Vascular Normalization: A New Window Opened for Cancer Therapies. *Front. Oncol.* 2021, 11, 719836. [CrossRef]
5. Matuszewksa, K.; Pereira, M.; Petrlik, D.; Lawler, J.; Petrlik, J. Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. *Cancers* 2021, 13, 4444. [CrossRef] [PubMed]
6. Nagy, J.A.; Chang, S.-H.; Dvorak, A.M.; Dvorak, H.F. Why are tumour blood vessels abnormal and why is it important to know? *Br. J. Cancer* 2009, 100, 865–869. [CrossRef]
7. Goel, S.; Wong, A.H.-K.; Jain, R.K. Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease. *Cold Spring Harb. Perspect. Med.* 2012, 2, a006486. [CrossRef]
8. Carmeliet, P.; Jain, R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat. Rev. Drug Discov.* 2011, 10, 417–427. [CrossRef]
9. Zhou, W.; Yang, L.; Nie, L.; Lin, H. Unraveling the molecular mechanisms between inflammation and tumor angiogenesis. *Am. J. Cancer Res.* 2021, 11, 301–317.
10. Dorrington, M.G.; Fraser, I.D.C.; Dorrington, M.G.; Fraser, I.D.C. NF-κB Signaling in Macrophages: Dynamics, Crossstalk, and Signal Integration. *Front. Immunol.* 2019, 10, 705. [CrossRef]
11. Mussbacher, M.; Salzmann, M.; Brostjan, C.; Hoesel, B.; Schoergenhofer, C.; Datler, H.; Hohensinner, P.; Basilio, J.; Petzelbauer, P.; Assinger, A.; et al. Cell Type-Specific Roles of NF-κB Linking Inflammation and Thrombosis. *Front. Immunol.* 2019, 10, 85. [CrossRef] [PubMed]
12. Moothy, A.K.; Savinova, O.V.; Ho, J.Q.; Wang, V.Y.F.; Vu, D.; Ghosh, G. The 20S proteasome processes NF-κB1 p105 into p50 in a translation-independent manner. *EMBO J.* 25, 1945–1956. [CrossRef] [PubMed]
13. Hoesel, B.; Schmidt, J.A. The complexity of NF-κB signaling in inflammation and cancer. *Mol. Cancer* 2013, 12, 86. [CrossRef]
14. Napetschnig, J.; Wu, H. Molecular Basis of NF-κB Signaling. *Annu. Rev. Biophys.* 2013, 42, 443–468. [CrossRef]
15. Kisseleva, T.; Song, L.; Vorontchikhina, M.; Feirt, N.; Kitajewski, J.; Schindler, C. NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancer. *J. Clin. Investig.* 2006, 116, 2955–2963. [CrossRef]
16. Denk, A.; Goebeler, M.; Schmid, S.; Berberich, I.; Ritz, O.; Lindemann, D.; Ludwig, S.; Wirth, T. Activation of NF-κB via the IkB Kinase Complex Is Both Essential and Sufficient for Proinflammatory Gene Expression in Primary Endothelial Cells. *J. Biol. Chem.* 2001, 276, 28451–28458. [CrossRef] [PubMed]
17. Malhab, L.J.B.; Saber-Ayad, M.M.; Al-Hakm, R.; Nair, V.A.; Paliogiannis, P.; Pintus, G.; Abdel-Rahman, W.M. Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation. Curr. Pharm. Des. 2021, 27, 2156–2169. [CrossRef]

18. Hallmann, R.; Hannocks, M.-J.; Song, J.; Zhang, X.; Di Russo, J.; Luik, A.-L.; Burmeister, M.; Gerwien, H.; Sorokin, L. The role of basement membrane laminins in vascular function. Int. J. Biochem. Cell Biol. 2020, 127, 105823. [CrossRef]

19. Di Russo, J.; Luik, A.; Yousif, L.; Budny, S.; Oberleithner, H.; Hofschröer, V.; Klingauf, J.; van Bavel, E.; Bakker, E.; Hellstrand, P.; et al. Endothelial basement membrane laminin 511 is essential for shear stress response. EMBO J. 2016, 36, 183–201. [CrossRef]

20. Baluk, P.; Morikawa, S.; Haskell, A.; Mancuso, M.; McDonald, D.M. Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Amyotrophic Lateral Sclerosis (ALS). J. Pathol. 2003, 163, 1801–1815. [CrossRef]

21. Martínez-Rey, D.; Carmona-Rodríguez, L.; Fernández-Aceñero, M.J.; Mira, E.; Mañes, S. Extracellular Superoxide Dismutase, the Endothelial Basement Membrane, and the WNT Pathway: New Players in Vascular Normalization and Tumor Infiltration by T-Cells. Front. Immunol. 2020, 11. [CrossRef]

22. Pozzi, A.; Yurchenco, P.; Iozzo, R.V. The nature and biology of basement membranes. Matrix Biol. 2017, 57–58, 1–11. [CrossRef] [PubMed]

23. Yousif, L.F.; Di Russo, J.; Sorokin, L. Laminin isoforms in endothelial and perivascular basement membranes. Cell Adhes. Migr. 2013, 7, 101–110. [CrossRef] [PubMed]

24. Yamada, M.; Sekiguchi, K. Molecular Basis of Laminin—Integrin Interactions. Curr. Top. Membr. 2015, 76, 197–229. [CrossRef] [PubMed]

25. Artimori, T.; Miyazaki, N.; Mihara, E.; Takizawa, M.; Taniguchi, Y.; Cabañas, C.; Sekiguchi, K.; Takagi, J. Structural mechanism of laminin recognition by integrin. Nat. Commun. 2021, 12, 4012. [CrossRef]

26. Sixt, M.; Engelhardt, B.; Pausch, F.; Hallmann, R.; Wendler, O.; Sorokin, L.M. Endothelial Cell Laminin Isoforms, Laminins 8 and 5, Play Decisive Roles in T Cell Recruitment across the Blood-Brain Barrier in Experimental Autoimmune Encephalomyelitis. J. Cell Biol. 2001, 153, 933–946. [CrossRef]

27. Warren, K.J.; Iwami, D.; Harris, D.; Bromberg, J.S.; Burrell, B.E. Laminins affect T cell trafficking and allograft fate. J. Clin. Invest. 2014, 124, 2204–2218. [CrossRef]

28. Wu, C.; Ivars, F.; Anderson, P.; Hallmann, R.; Vestweber, D.; Nilsson, P.; Robenek, H.; Tryggvason, K.; Song, J.; Korpos, E.; et al. Endothelial basement membrane laminin α5 selectively inhibits T lymphocyte extravasation through the brain. Nat. Med. 2009, 15, 519–527. [CrossRef]

29. Kenne, E.; Soehnlein, O.; Genové, G.; Rotzius, P.; Eriksson, E.E.; Lindbom, L. Immune cell recruitment to inflammatory loci is impaired in mice deficient in basement membrane protein laminin α4. J. Leukoc. Biol. 2010, 88, 523–528. [CrossRef]

30. Zhang, X.; Wang, Y.; Song, J.; Gerwien, H.; Chuquisana, O.; Chashchina, A.; Denz, C.; Sorokin, L. The endothelial basement membrane acts as a checkpoint for entry of pathogenic T cells into the brain. J. Exp. Med. 2020, 217, e20191339. [CrossRef]

31. Song, J.; Zhang, X.; Buscher, K.; Wang, Y.; Wang, H.; Di Russo, J.; Li, L.; Lütke-Enking, S.; Zarbock, A.; Stadtmann, A.; et al. Endothelial basement membrane laminin 511 contributes to endothelial junctional tightness and thereby inhibits leukocyte transmigration. Cell Rep. 2017, 18, 1256–1269. [CrossRef]

32. Carmona-Rodríguez, L.; Martínez-Rey, D.; Fernández-Aceñero, M.J.; González-Martín, A.; Cabezás, M.P.; Rodríguez-Rodríguez, N.; Pérez-Villamil, B.; Sáez, M.E.; Díaz-Rubio, E.; Mira, E.; et al. SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells. J. Immunother. Cancer 2020, 8, e000432. [CrossRef] [PubMed]

33. Carmona-Rodríguez, L.; Martínez-Rey, D.; Mira, E.; Mañes, S. SOD3 boosts T cell infiltration by normalizing the tumor endothelium and inducing laminin α4. Oncoimmunology 2020, 9, 1794163. [CrossRef] [PubMed]

34. Petersen, S.V.; Olsen, D.A.; Kenney, J.M.; Oury, T.D.; Valnickova, Z.; Thøgersen, I.B.; Mancuso, M.; McDonald, D.M. Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Amyotrophic Lateral Sclerosis (ALS). PLoS ONE 2010, 5, e9541. [CrossRef]

35. Bolstad, B.; Irizarry, R.; Astrand, M.; Speed, T. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19, 185–193. [CrossRef]
